Introduction
Patients’ well-being is a major concern in rheumatoid arthritis (RA). Patients with RA suffer from a variety of symptoms such as joint pain and swelling, stiffness, fatigue and functional disability, that impair their quality of life. Sleep disturbances are also common in this population and contribute to the problem.1 Several studies have found sleep fragmentation, low sleep efficiency, frequent awakenings and poor sleep quality in this group of patients.1-3
Nicassio et al.4 consider pain and sleep disturbance to be closely linked. However it is difficult to know which one is the primary problem. Although the inflammatory process brought by RA activity is responsible for pain initiation, investigators have found that, in some patients, pain intensity may be out of proportion to the severity of inflammation.5 It is believed that this is due to central nervous system pain amplification, mainly due to diminished conditioned pain modulation.5 Psychological distress, most notably depression and/or anxiety is another variable implicated in this relationship.1,4
To look further into this issue, we have studied a sample of RA Brazilian patients in order to clarify the associations of sleep quality with pain, depression and disease activity.
Methods
After approval of the local Committee of Ethics in Research and signed consent from patients we studied 112 RA patients from a single University Center. This was a convenience sample of patients that came for regular consultations in the period of one year and accepted to participate in the study. All subjects had to fulfill at least four 1987 ACR criteria for RA classification.6 We excluded patients with age under 18 years, with disease beginning before 16 years, pregnant women, those with uncontrolled thyroid disease or with other chronic inflammatory condition and those using sleep inductor medications. We collected demographic, clinical and serological data, values of hemoglobin, ESR (erythrocyte sedimentation rate), CRP (C reactive protein) and DAS-28. Diurnal somnolence was evaluated by the Epworth scale,7 the index of sleep quality by the Pittsburg index,8 and the risk of sleep apnea by the Berlin questionnaire.9 Depression was measured by the CES-D Questionnaire or Center for Epidemiologic Studies Depression scale.10 All the applied instruments were translated and validated for the Portuguese language. Fatigue and global health were measured by a visual analogic scale from 0 (none) to 100 (maximal).
Patients were divided in those with good and poor sleep quality according to the Pittsburg index (equal or lower than 5 = good sleep; >5 = sleep disorder) and these two samples were compared. For this comparison we used Fisher and chi-squared tests for nominal data and Mann Whitney and unpaired t test for numerical data. Associations with p ≤ 0.10 were studied through linear regression to test the variables independence. Significance adopted was of 5%.
Results
Overview of studied sample and prevalence of sleep disturbances
In the 112 RA patients, 83.1% were female, with age ranging from 21 to 77 years (mean 55.4 ± 10.9 years) and disease duration from 9 months to 53 years (median 11 years; IQR or interquartile rate = 5-18). Auto declared Afro descendants were 19.6%; 1.7% Asiatic descendants and 78.5% Caucasians. Tobacco exposure occurred in 39.2% while 60.3% never smoked. The body mass index varied from 17.3 to 46.4 kg/m2 (median of 27.5; IQR = 24.3-31.5 kg/m2). Rheumatoid factor (RF) was present in 59.6%; anti-CCP in 47.6%; ANA (antinuclear antibody) in 34.9%.
Treatment profile at the time of study showed that prednisone was used in 71.4% (doses from 5.0 to 60.0 mg; median 5.0; IQR = 5.0-10.0); methotrexate in 73.2%, antimalarial in 21.4%, leflunomide in 43.7%, anti TNF-alpha in 5.3% and abatacept in 2.6%.
Table 1 shows the results of laboratory tests and applied questionnaires.
Table 1 Laboratory and questionnaires results in 112 rheumatoid arthritis patients.
Studied variable | Values |
---|---|
Erythrocyte sedimentation rate (mm/h) | 1-103 (median 35.0; IQR = 19.7-58.0) |
C reactive protein (mg/dL) | 0.15-80.0 (median 10.9; IQR = 5.0-20.7) |
Hemoglobin | 10.9-16.9 (mean 13.3 ± 1.2) |
VAS global | 0-100 (median 30.0; IQR = 30.0-60.0) |
VAS pain | 0-100 (median 60.0; IQR 30.0-80.0) |
VAS fatigue | 0-100 (median 50.0; IQR 0-80.0) |
Body mass index (kg/m2) | 17.3-46.4 (median 27.5; IQR = 24.3-31.5) • Underweight (<18.5) - 4/112 = 3.5% • Normal (18.6-24.9) - 29/112 = 25.8% • Overweight (25-29.9) - 43/112 = 38.3% • Obesity (≥30) - 36/112 = 32.1% |
DAS-28 (ESR) | 0.28-7.38 (mean 3.75 ± 1.28) |
Epworth sleepiness scale | 0-24.0 (median 6.0; IQR 3.0-12.0) • Normal = 79/112 (70.5%) • Pathological somnolence = 12/112 (10.7%) • Significant somnolence = 21/112 (18.7%) |
Berlin or sleep apnea screening questionnaire | 0-3.0 (median 1.0; IQR = 3.0-2.0) • Low risk of sleep apnea = 58/112 (51.7%) • High risk of sleep apnea = 54/112 (48.2%) |
Pittsburg sleep quality index | 1-18 (median 9.0; IQR 5.0-18.0) • Sleep of good quality = 21/112 (18.5%) • Sleep disturbance = 47/112 (41.9%) • Bad sleep = 44/112 (39.2%) |
Center for Epidemiologic Studies Depression Scale (CES-D) | 0-60 (median 13.0; IQR = 6.0-22.0) • Normal - 63/112 = 56.1% • Depressive - 49/112 = 43.7% |
VAS, visual analogic scale; DAS-28, Disease Activity Score Calculator.
Comparison study of RA patients with good and poor sleep quality
Studying the comparison of patients with and without good sleep quality according to the Pittsburg index we obtained the results in Table 2.
Table 2 Comparison of demographic, laboratorial, serological and treatment data in rheumatoid arthritis patients according to sleep quality measured by Pittsburg index (good sleep ≤ 5; sleep disorder > 5).
Pittsburg index ≤ 5 n = 21 |
Pittsburg index > 5 n = 91 |
p | |
---|---|---|---|
Gender (male/female) | 5/16 | 13/78 | 0.32a |
Tabagism (smokers/not smokers) | 5.2% | 14.2% | 1.00a |
Ethnic background (Afrodescendants/Caucasians) | 2/18 | 20/71 | 0.35a |
Mean age (years) | 58.4 ± 2.2 | 54.7± 10.6 | 0.15b |
Mean age at diagnosis (years) | 45.0 ± 15.6 | 42.5 ± 11.56 | 0.42b |
Median body mass index (kg/m2) | 26.7 (IQR = 22.3-28.6) |
27.6 (IQR = 24.7-31.59) |
0.25c |
Positive rheumatoid factor | 47.6% | 61.5% | 0.24c |
Positive anti-CCP | 30% | 50.9% | 0.30a |
Positive antinuclear antibody | 40% | 33.7% | 0.59d |
Median C reactive protein (mg/L) | 11.0 (IQR = 6.0-20.8) |
10.7 (IQR = 5.0-20.7) |
0.85c |
Median hemoglobin (g/dL) | 13.5 (IQR = 12.0-14.0) |
13.4 (IQR = 12.4-14.0) |
0.80c |
Median prednisone dose (mg/day) | 5.0 (IQR = 0.0-5.0) |
5.0 (IQR = 5.0-10.0) |
0.03c |
Metotrexate users | 71.4% | 73.9% | 0.83d |
Leflunomide users | 42.8% | 43.9% | 0.92d |
Antimalarial users | 19.04% | 21.9% | 1.00a |
Biologic medication users | 9.5% | 9.8% | 1.00a |
Median sedimentation rate | 26.0 (IQR = 13.5-47.5) |
39.0 (IQR = 21.0-60.0) |
0.12c |
IQR, interquartile rate.
aFisher test.
bUnpaired t test.
cMann Whitney test.
dChi squared test.
The result of DAS 28 (ESR) in the samples with and without good sleep quality is seen in Fig. 1.

Fig. 1 Comparison of DAS-28 (ESR) according to sleep quality measured by Pittsburg index (p = 0.01; Mann Whitney). Comparison of ESR with p = 0.12; global VAS with p = 0.43; number of swollen joints with p = 0.31; number of painful joints with p = 0.005.
The comparison of VAS fatigue, Epworth sleepiness scale and Berlin sleep apnea screening questionnaire showed respectively p = 0.04, p = 0.84 and p = 0.06 (Mann Whitney). The result of association of Pittsburg index with depression (CES-D) is in Fig. 2.

Fig. 2 Association study of depression measured by CES-D and sleep quality measured by Pittsburg index (p = 0.0005).
In a multiple regression study that included daily doses of prednisone, VAS fatigue, number of tender joints, results of Berlin sleep apnea screening questionnaire, Depression CES-D questionnaire and number of painful joints (from DAS 28), we found that the Pittsburg index associated independently with CES-D depression questionnaire (p = 0.008) and Berlin apnea screening questionnaire (p = 0.004).
Discussion
One of the most striking findings of the present study is that less than 20% of RA patients have a sleep of good quality. This must be taken into account in daily practice if one intends to improve patients’ quality of life. This high prevalence of sleep disorder has already been noted by others.1-4
In this study, univariate analysis disclosed association of poor sleep with DAS 28, daily dose of prednisone, fatigue, depression and risk of sleep apnea. Sariyildiz et al.1 and Son et al.11 have also found association of disease activity with poor sleep quality. Some studies have documented qualitative alterations and rupture in sleep continuity in relationship with certain immunological factors.12 In RA, circulating TNF-α is increased and there has been a suggestion that the level of this cytokine may be connected to sleep disorders.12 Brain levels of IL-1 and TNFα are linked with sleep deprivation.12 One study13 conducted in ten RA patients to assess whether anti TNF drugs had any effect on the sleep pattern suggested that its quality improved with this type of medication.
However, in the present study, when the elements that are included in the DAS 28 were examined apart, the number of tender joint was the component responsible for the association. Thus, pain and not inflammation could be the real association. Sleep disturbance in patients with joint pain has been noted not only in RA but in other chronic painful conditions.14
The daily dose of prednisone was also related to lower performance in the Pittsburg score in univariate analysis. Endogenous glucocorticoids are critical for the pathogenesis of sustained stress-related sleep disorders.15 High serum levels of glucocorticoids induce poor sleep quality and shorter sleep duration through receptors that are highly expressed in the brain.16 Nevertheless, higher doses of prednisone are used by patients with more inflammation and it is possible that, again, pain resulting from the inflammatory process could be the true responsible for the relationship.
The Berlin apnea screening questionnaire displayed an independent association with poor sleep in RA. Drossaers-Baker et al.17 showed that sleep apnea in their RA patients was due to a mixed pattern: central and obstructive, suggesting that this problem is multifactorial. Contributors to the obstructive component could be increased neck circumference by glucocorticoid use, narrowing of upper airway by changes in temporomandibular joint, reposition of cervical axis in cases of cervical subluxation or even by diminished muscle tone in the airway.17 A high BMI is also common in RA patients and was found in 60% of this sample. Vertical luxation of the odontoid process may cause compression of the brain stem and could result in central impairment of breathing.18 Patients with hypoventilation complain of headache upon awakening, nocturnal unrest, day-time sleepiness and impaired concentration.19 These symptoms are often mild and may be easily overlooked. Curiously, anti TNF drugs are also described as improving the sleep apnea syndrome.19 In our sample the number of patients using this type of drug was too small to allow any conclusions.
Finally, depression was independently linked to poor sleep quality. Depression is a highly prevalent problem in RA1 and contributes to disability, bad adherence to treatment, and poor social functioning. Insomnia in depressed patients was first considered to be a symptom of depression.20 More recently there is evidence to sustain that there is a bidirectional connection between these two variables. According to some studies, sleep disorder is also a major risk factor for future onset and for recurrence of depressive episodes.21,22
Concluding, the present data show a high prevalence of poor sleep in RA patients and that the main associated factors are sleep apnea and depression.